Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.

BackgroundA test that helps predict the time to the final menstrual period (FMP) has been sought for many years.ObjectiveTo assess the ability of antimullerian hormone (AMH) measurements to predictions the time to FMP.DesignProspective longitudinal cohort study.SettingThe Study of Women's Health Across the Nation.Participants and measurementsAMH and FSH were measured in 1537 pre- or early perimenopausal women, mean age 47.5 ± 2.6 years at baseline, then serially until 12 months of amenorrhea occurred. AMH was measured using a 2-site ELISA with a detection limit of 1.85 pg/mL.Main outcome measureAreas under the receiver operating curves (AUC) for AMH-based and FSH-based predictions of time to FMP, stratified by age. Probabilities that women would undergo their FMP in the next 12, 24, or 36 months across a range of AMH values were assessed.ResultsAUCs for predicting that the FMP will occur within the next 24 months were significantly greater for AMH-based than FSH-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within the next 12 months ranged from 51% at h100 pg/mL would not undergo her FMP within the next 12 months ranged from 97% in women <48 years old to 90% in women ≥51 years old.ConclusionsAMH measurement helps estimate when a woman will undergo her FMP, and, in general, does so better than FSH.